| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Alphamab Oncology (HK: 9966)
9966 Technical Analysis
5
| As on 12th Sep 2025 9966 STOCK Price closed @ 12.44 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.55 & Strong Buy for SHORT-TERM with Stoploss of 4.44 we also expect STOCK to react on Following IMPORTANT LEVELS. |
9966STOCK Price
| Open | 11.12 | Change | Price | % |
| High | 12.49 | 1 Day | 1.94 | 18.48 |
| Low | 11.12 | 1 Week | 2.89 | 30.26 |
| Close | 12.44 | 1 Month | 3.01 | 31.92 |
| Volume | 11674500 | 1 Year | 7.48 | 150.81 |
| 52 Week High 10.98 | 52 Week Low 2.12 | ||||
HK Hong Kong Most Active Stocks
| 0020 | 2.26 | 7.11% |
| 0020-OL | 2.26 | 7.11% |
| CSHK100 | 2354.52 | 1.46% |
| 2007 | 0.66 | 6.45% |
| 1918 | 1.87 | 8.72% |
| 6666 | 1.11 | 20.65% |
| 1341 | 0.28 | -6.67% |
| 43 | 1.14 | 0.00% |
| 3377 | 0.17 | 13.33% |
| 0813 | 0.42 | 2.44% |
HK Hong Kong Top Gainers Stocks
HK Hong Kong Top Losers Stocks
| 9966 Daily Charts |
9966 Intraday Charts |
Whats New @ Bazaartrend |
9966 Free Analysis |
|
|
9966 Important Levels Intraday
| RESISTANCE | 15.08 |
| RESISTANCE | 14.23 |
| RESISTANCE | 13.71 |
| RESISTANCE | 13.19 |
| SUPPORT | 11.69 |
| SUPPORT | 11.17 |
| SUPPORT | 10.65 |
| SUPPORT | 9.80 |
9966 Forecast September 2025
| 4th UP Forecast | 16.04 |
| 3rd UP Forecast | 14.89 |
| 2nd UP Forecast | 14.17 |
| 1st UP Forecast | 13.46 |
| 1st DOWN Forecast | 11.42 |
| 2nd DOWN Forecast | 10.71 |
| 3rd DOWN Forecast | 9.99 |
| 4th DOWN Forecast | 8.84 |
9966 Weekly Forecast
| 4th UP Forecast | 13.98 |
| 3rd UP Forecast | 13.49 |
| 2nd UP Forecast | 13.18 |
| 1st UP Forecast | 12.88 |
| 1st DOWN Forecast | 12.00 |
| 2nd DOWN Forecast | 11.70 |
| 3rd DOWN Forecast | 11.39 |
| 4th DOWN Forecast | 10.90 |
9966 Forecast2025
| 4th UP Forecast | 32.65 |
| 3rd UP Forecast | 26.17 |
| 2nd UP Forecast | 22.16 |
| 1st UP Forecast | 18.16 |
| 1st DOWN Forecast | 6.72 |
| 2nd DOWN Forecast | 2.72 |
| 3rd DOWN Forecast | -1.29 |
| 4th DOWN Forecast | -7.77 |
Alphamab Oncology ( HK Hong Kong Symbol : 9966 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
9966 Business Profile
Alphamab Oncology, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China. Address: Building C23, Suzhou, China, 215024
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service